A b s t r a c t
Hemophilia A is a rare and often debilitating bleeding disorder due to deficiency of clotting factor VIII. Fortunately, coagulation factor replacement products exist to provide effective prevention and treatment for hemophilia bleeding complications. Nevertheless, the potential for morbidity and mortality still exists, and treatment is associated with high costs. Factor replacement therapy accounts for nearly 90% of health care costs incurred during hospital stays by patients with hemophilia. 1 Any attempt to improve the use of replacement factors must overcome several substantial barriers. First, because patients with hemophilia are hospitalized for various reasons, their attending physicians have backgrounds in many specialties but frequently lack specific training in the management of hemorrhagic diatheses. Moreover, owing to the low prevalence of hemophilia, most physicians treat such patients only sporadically and never become familiar with variations in clinical manifestations and differences in their management with coagulation factor concentrates. Thus, the ability of an institution to provide a unified approach to treating hemophilia could ensure high-quality and cost-effective care.
Data on the cost of coagulation replacement therapy are confounded by the use of dissimilar accounting systems and by differences in distribution points, services, and methods. 1 Moreover, we are not aware of any study describing the cost of treating patients with coagulation factors in an inpatient setting in the United States. While product use in this setting may represent only a relatively small proportion of the total, it nevertheless can contribute substantially to an institution's expenses. Thus, analysis of inpatient coagulation product use could have considerable impact by providing insight for better utilization of health care resources in this area.
In our institution, the transfusion medicine service stocks and distributes factor concentrates. A review of the transfusion medicine records from August 1998 to July 1999 showed the acquisition cost for factor concentrates was almost $700,000. Consequently, we reviewed laboratory documentation for all patients who were treated with coagulation factor concentrates during the same 12 months, the types and doses of replacement products, and the results of plasma coagulation factor assays performed during treatment. Following the review, the transfusion medicine service enacted new procedures to enable more consistent and efficient use of these expensive products.
The objective of this report is 2-fold: (1) to illustrate the impact of a policy that requires clinical pathology consultation before issuing coagulation factors from the transfusion medicine service and (2) to describe the magnitude of 1 institution's inpatient cost for replacement therapy in hemophilia and other single-factor deficiencies.
Materials and Methods
The institutional review board of the University of Alabama at Birmingham (UAB) approved this study, which was conducted in 2 parts: retrospective and prospective gathering of data from laboratory records.
Retrospective Review
We retrieved transfusion service billing records for UAB University Hospital inpatients who had been prescribed coagulation factor concentrates from August 1998 to July 1999. Data analysis included cost linked with patient identity, diagnosis, admitting physician service, reason for treatment, dates of treatment, type and dose of factor concentrate, and results of plasma factor level assays. Coagulation factor purchase costs (not charges to patients) were used for consistency. Acquisition costs were normalized on a per unit basis for the calculations throughout the study and were as follows: plasma-derived factor VIII, $0.35; recombinant factor VIII, $0.68; activated prothrombin complex concentrate, $0.78; porcine factor VIII, $1.29; von Willebrand factor, $0.65; plasma-derived factor IX, $0.55; and prothrombin complex concentrate, $0.40.
Intervention and Data Acquisition
In August 1999, we instituted a mandatory clinical pathology consultation policy. A resident and attending pathologist reviewed each coagulation factor order and recommended product selection, dosage, and follow-up testing. The steps of the intervention are listed in ❚Table 1❚. Before implementation of this policy, pathology approval was required only if it were the patient's first treatment in our institution, and there was no standardized approach to the consultation process.
Hemophilia Patient Database
During the retrospective review, we simultaneously established a database of patients with single-factor deficiencies treated in our institution. Although the most common diagnosis was hemophilia A, congenital or acquired, there also were patients with von Willebrand disease, hemophilia B, and prothrombin deficiency. The database contains patient name and medical record number, age, deficient factor, presence and titer of factor inhibitors, serologic testing results for HIV and hepatitis B or C, date and time of treatment, type and dose of product, and factor level assay results. By consulting database records for returning patients, we were able to make preliminary replacement factor selections without repeating lengthy diagnostic procedures. For example, for patients with known high-titer factor VIII inhibitor, titers were not rechecked every time the patients required treatment.
Statistical Analysis
We used the Student t test for the comparison of means of factor levels, length of treatment, and number of units of RBCs transfused before and after mandatory clinical pathology consultation.
Results

Retrospective Review of Coagulation Factor Use
A review of the UAB University Hospital records provided the baseline for understanding reasons for hemophilia inpatient treatment and use of clotting factors. Throughout the 12-month retrospective review period, 14 patients were admitted for diverse indications, including spontaneous bleeding, dental extractions, orthopedic procedures, Owing to the variety of reasons for admissions, 6 different specialty and subspecialty services admitted patients with single-factor deficiencies during this period. Patients admitted during the baseline, retrospective review year were considered "new" for the purposes of analyzing the data. Subsequent admissions of the same person were defined as "returning" patient. ❚Table 3❚ depicts the numbers of new and returning patients treated during the study. During the 3.5 years for which data were collected, 16 (41%) of 39 patients had more than 1 hospital admission during which factor replacement was required. Among the patients hospitalized repeatedly, 44% (7/16) had hemophilia A, 38% (6/16) had hemophilia A with inhibitor or acquired hemophilia (HAI), and 19% (3/16) had other disorders. With the admissions from the first year of the study used as the baseline, 37% (7/19) of patients with hemophilia A and 50% (6/12) of patients with HAI required at least 1 more hospitalization during the next 2.5 years. For a given person, the number of repeated hospitalizations varied from 0 to 6, except for 1 patient with hemophilia A and an inhibitor who was admitted 13 times. For hemophilia A and HAI, the mean numbers of hospitalizations were 1.7 and 3.6, respectively (P = .24).
Pathology Consultations
Data on pathology consultations before issuing coagulation factors were obtained by reviewing the computer records of the transfusion medicine service. Pathology residents had been consulted 46% of the time during the baseline year, or in 12 of 26 patient admissions. Since the intervention, consultations were requested 79% of the time during the first year and 90% of the time for the remainder of the study period. In addition, the patient care team implemented all recommendations for dose and type of product after discussion with the clinical pathology consultants.
Impact of Intervention
We calculated the economic impact of mandatory consultation by comparing the preintervention and postintervention mean cost per day and mean total cost per treatment for the 2 most common diseases, hemophilia A and HAI. In the calculations for the cost of treating HAI, we included patients with hemophilia A and inhibitor and patients with acquired hemophilia. The results are given in ❚Table 4❚. After the intervention, the average cost of coagulation product per admission dropped $2,564 (approximately 27%) for patients with hemophilia A. For patients with hemophilia A with inhibitors, there was a $1,689 reduction per hospitalization (approximately 6%). Considering coagulation factor cost only, a total cost reduction of $108,828 occurred after mandatory clinical pathologist involvement during a 30-month period.
The number of treatments for hemophilia B, von Willebrand disease, and prothrombin deficiency were too small to study the effect of the intervention. The cost of replacing factor IX ranged from $280 to $4,904 (3 treatments), while treatment with von Willebrand factor averaged $7,288 (8 treatments). One patient with prothrombin deficiency who was admitted 3 times received prothrombin complex concentrate at a cost ranging from $814 to $2,441 per hospitalization.
Factor Assay Levels and Clinical Outcomes
The results of the factor levels achieved during treatment with factor concentrates are given in ❚Table 5❚. The analysis combined all factor levels (VIII, IX, von Willebrand factor, and prothrombin) because the target therapeutic levels are similar among the factor deficiencies. Since in the preintervention period there were consultations in half of the cases, we calculated the data to reflect the result of the factor levels in cases with and without pathology involvement in the dose selection process. Table 5 shows that the levels achieved in the patients for whom consultation was done before release of the factor concentrates did not vary before or after mandatory consultation, as opposed to when no consultation was obtained. Another way to compare the results of the factor levels is to calculate the percentage of the assays that were above therapeutic level, which we defined as more than 100% (Table 5) . The goal of therapy should be to reach levels that are required for effective hemostasis without wastage of resources. Despite receiving lower doses of factor during the postintervention period, however, patients did not require more RBC transfusions. In fact, the average number of units transfused decreased after the intervention, although the difference did not reach statistical significance ❚Table 6❚. Furthermore, the length of coagulation factor treatment was comparable, independent of the indication for treatment, before and after mandatory pathology intervention (Table 6 ).
Discussion
Our data confirm the high cost of treating adults with coagulation factor deficiencies. During 3.5 years, our institution spent more than $1.4 million (using 1999 acquisition costs) on replacement factor products for inpatients with hemophilia A. Because we used unit costs, our calculations may be generalized to other cost centers for utilization review comparison.
Our data also showed the complexity of patients with single coagulation factor deficiencies by revealing the large number of medical specialists who cared for the patients. In our tertiary care center, at least 6 medical and surgical services admitted patients with coagulation deficiencies. The diversity of admitting physicians suggested a lack of expertise and/or experience with these disorders as a possible cause for the institution's failure to follow established guidelines for factor replacement as evidenced by the high proportion of The results of the present study strongly suggest significant benefit from clinical pathology consultation in the management of hospitalized patients with hemophilia. However, this was a retrospective study and was not randomized or controlled for the many indications for which patients with hemophilia require hospitalization. The data do not indicate that the clinical situations before and after intervention were, in fact, identical. Therefore, given the relatively small numbers in this study, the exact role of the consultation in cost-effective care cannot be stated unequivocally. The clinical settings in which the most benefit from clinical pathology consultation might occur and whether and when little benefit might exist remain to be defined. The fact that the greatest benefit occurred with patients with hemophilia without inhibitors rather than those with inhibitors suggests that the consultative process leads to an improvement in cost-effective care if complex choices exist. Consultation may not make expensive care more cost-effective in the absence of viable alternatives. Future randomized studies that evaluate one-time vs ongoing multiday consultation and the integration of factor levels with dosing changes might further clarify the role of consultation in the provision of cost-effective care. Moreover, the introduction of newer agents, such as recombinant activated factor VII for patients with factor VIII inhibitor, provides a potential opportunity to study the changing role of the consultative process over time as the therapeutic choices grow.
The cost of hemophilia treatment continues to increase, creating a need for accurate and generally applicable economic data collection. [4] [5] [6] An informed society demands accountability for hemophilia therapy at a time when even wealthy nations are limiting resources expended in chronic disease management. 6 Our data collection system may be applied to track the cost of new therapeutic products as they are developed and the use of current and new products for prophylaxis or immune tolerance induction.
patients who received excessive doses of factors. Since only the transfusion service releases coagulation factors at our institution, we were able to establish a nearly universal intervention to provide consistent hemophilia care. We showed that prospective clinical pathology consultation could effectively guide coagulation factor replacement treatment and reduce costs. The program produced an approximate 35% reduction in the daily cost ($2,720 to $1,764) and slightly more than $2,500 average savings in factor VIII replacement per hospitalization for treatment of hemophilia A. The program also generated a modest improvement in the treatment of patients with inhibitors to factor VIII. While the average daily cost rose minimally (approximately 2%), the average cost per admission decreased by approximately 6%, because of an overall decrease in treatment days.
The greatest savings occurred with the treatment for adults with hemophilia A and derived from 2 aspects of the treatment: (1) fewer units dispensed and (2) increased use of plasma-derived products for patients previously infected with HIV or hepatitis B or C. Because our patients were adults, many had become infected with one or more of these viruses (data not shown). The potential improved margin of safety conferred by recombinant products becomes virtually negligible for patients already infected with one of these viruses. 2 In contrast, smaller savings occurred for patients with factor VIII inhibitors because the product selection was limited to an activated prothrombin complex concentrate (FEIBA, Baxter, Deerfield, IL) during the study period. Furthermore, fewer variations in dosing guidelines exist for FEIBA compared with straight factor VIII replacement. Goudemand 3 states that the annual cost to treat patients with high-titer inhibitors was 12 times that of patients without inhibitors. In our hands, the cost of each treatment series for patients with inhibitors was approximately 4-fold higher than that for patients with hemophilia A without inhibitors. Furthermore, patients with inhibitors tended to require more treatments per year, further increasing the difference between the 2 groups. HA, hemophilia A; HAI, hemophilia A with inhibitor or acquired hemophilia. * P = .63 compared with preintervention. † P = .52 compared with preintervention. ‡ P = .64 compared with preintervention. § P = .66 compared with preintervention. || P = .44 compared with preintervention.
¶ P = .24 compared with preintervention.
Laboratory medicine professionals pursue 3 broad purposes: provision of laboratory data, control of laboratory utilization, and quality assurance. 7 Clinical pathologists have a unique opportunity to improve patient care through consultation, thereby meeting all 3 purposes and adding measurable value to laboratory services. Communication with medical and surgical services improves patient outcomes while maintaining scarce resources. 8 Popovsky and Triulzi 9 advocate the role of the transfusion medicine specialist as educating health care colleagues to improve transfusion safety and decrease costs. The present study provides a good example. Our expert pathology initiative integrates various laboratory services with the patient service unit to achieve economic, safe, and, ultimately, consistent hemophilia care.
